| Primary |
| Hiv Infection |
83.2% |
| Prophylaxis Against Hiv Infection |
3.5% |
| Product Used For Unknown Indication |
2.1% |
| Acquired Immunodeficiency Syndrome |
1.9% |
| Pelvic Inflammatory Disease |
1.6% |
| Cardiac Disorder |
1.1% |
| Contraception |
0.8% |
| Hypertension |
0.8% |
| Prophylaxis |
0.8% |
| Candidiasis |
0.5% |
| Drug Abuser |
0.5% |
| Essential Hypertension |
0.5% |
| Gastroduodenal Ulcer |
0.5% |
| Tuberculosis |
0.5% |
| Bipolar Disorder |
0.3% |
| Convulsion |
0.3% |
| Depression |
0.3% |
| Diabetes Mellitus |
0.3% |
| Drug Abuse |
0.3% |
| Glomerulonephritis |
0.3% |
|
| Ventricular Septal Defect |
10.8% |
| Abortion Spontaneous |
9.2% |
| Stillbirth |
7.7% |
| Death Neonatal |
6.2% |
| Hypoplastic Right Heart Syndrome |
6.2% |
| Pregnancy |
6.2% |
| Tuberculosis |
6.2% |
| Liver Disorder |
4.6% |
| Pneumonia |
4.6% |
| Thrombocytopenia |
4.6% |
| Toxic Epidermal Necrolysis |
4.6% |
| Vomiting |
4.6% |
| Haematuria |
3.1% |
| Oedema Peripheral |
3.1% |
| Osteonecrosis |
3.1% |
| Pre-eclampsia |
3.1% |
| Renal Failure |
3.1% |
| Renal Failure Acute |
3.1% |
| Respiratory Failure |
3.1% |
| Toxic Skin Eruption |
3.1% |
|
| Secondary |
| Hiv Infection |
65.7% |
| Antiretroviral Therapy |
10.4% |
| Drug Use For Unknown Indication |
5.3% |
| Acquired Immunodeficiency Syndrome |
3.3% |
| Product Used For Unknown Indication |
2.8% |
| Mycobacterium Avium Complex Infection |
2.7% |
| Drug Exposure During Pregnancy |
1.8% |
| Antifungal Prophylaxis |
0.9% |
| Antibiotic Prophylaxis |
0.8% |
| Antiviral Prophylaxis |
0.8% |
| Fungal Infection |
0.7% |
| Hypertension |
0.7% |
| Pulmonary Tuberculosis |
0.7% |
| Asymptomatic Hiv Infection |
0.5% |
| Cytomegalovirus Infection |
0.5% |
| Hepatitis B |
0.5% |
| Hiv Test Positive |
0.5% |
| Supplementation Therapy |
0.5% |
| Contraception |
0.4% |
| Immune Reconstitution Syndrome |
0.4% |
|
| Stillbirth |
11.1% |
| Renal Failure Acute |
7.9% |
| Vomiting |
7.1% |
| Abortion Spontaneous |
6.3% |
| Subdural Haematoma |
6.3% |
| Drug Exposure During Pregnancy |
5.6% |
| Vaginal Haemorrhage |
5.6% |
| Ventricular Septal Defect |
5.6% |
| Immune Reconstitution Syndrome |
4.8% |
| Osteoporosis |
4.8% |
| Pregnancy |
4.8% |
| Hypoplastic Right Heart Syndrome |
4.0% |
| Thrombocytopenia |
4.0% |
| Hodgkin's Disease |
3.2% |
| Maternal Exposure During Pregnancy |
3.2% |
| Nephrolithiasis |
3.2% |
| Rash Maculo-papular |
3.2% |
| Skin Disorder |
3.2% |
| Urticaria |
3.2% |
| Weight Decreased |
3.2% |
|
| Concomitant |
| Hiv Infection |
57.3% |
| Drug Use For Unknown Indication |
8.3% |
| Product Used For Unknown Indication |
6.7% |
| Drug Exposure During Pregnancy |
3.8% |
| Back Pain |
3.4% |
| Depression |
2.9% |
| Hepatitis C |
2.7% |
| Acquired Immunodeficiency Syndrome |
2.5% |
| Antiretroviral Therapy |
1.9% |
| Hiv Test |
1.8% |
| Injection Site Reaction |
1.1% |
| Prophylaxis |
1.1% |
| Prostatism |
1.1% |
| Hypertension |
1.0% |
| Mycobacterium Avium Complex Infection |
1.0% |
| Anorexia |
0.7% |
| Asthma |
0.7% |
| Pain |
0.7% |
| Anxiety |
0.6% |
| Blood Cholesterol Increased |
0.6% |
|
| Oedema Peripheral |
10.3% |
| Renal Failure |
8.5% |
| Renal Failure Acute |
6.8% |
| Weight Decreased |
6.0% |
| Hypothermia |
5.1% |
| Renal Impairment |
5.1% |
| Stillbirth |
5.1% |
| Ventricular Septal Defect |
5.1% |
| Vertigo |
5.1% |
| Cerebral Haemorrhage |
4.3% |
| Hypersensitivity |
4.3% |
| Osteonecrosis |
4.3% |
| Prothrombin Time Prolonged |
4.3% |
| Urosepsis |
4.3% |
| Wound Infection |
4.3% |
| Menometrorrhagia |
3.4% |
| Pathological Fracture |
3.4% |
| Pericardial Effusion |
3.4% |
| Renal Tubular Disorder |
3.4% |
| Spinal Compression Fracture |
3.4% |
|
| Interacting |
| Product Used For Unknown Indication |
93.1% |
| Hiv Infection |
6.9% |
|
| Abdominal Pain |
25.0% |
| Megacolon |
25.0% |
| Night Sweats |
25.0% |
| Potentiating Drug Interaction |
25.0% |
|
